Takeda Pharmaceutical Company Limited ("Takeda") and Pfizer Japan Inc. ("Pfizer") announced that they have concluded an agreement that, as of December 31, 2012, Takeda will cease distribution of 13 out of the 15 Pfizer products that it previously procured from Wyeth K.K. and currently distributes under an exclusive distribution agreement with Pfizer, and that Pfizer, the manufacturer of the products, will begin selling them thereafter. In addition, Takeda will continue to distribute the pneumococcus vaccine Prevenar® for infants and young children and hemophilia B drug BeneFIX® (generic name: nonacog alfa) after January 2013.

Aside from this exclusive distribution agreement, the two companies agreed in February 2011 to extend the term of co-promotion agreement of the rheumatoid arthritis (RA) drug Enbrel® (generic name: etanercept), the marketing of which Takeda will continue.

Takeda and Pfizer will remain committed to the prevention and treatment of diseases by providing drugs that meet the needs of patients and medical professionals through their successful partnership.

About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine.

About Pfizer
Pfizer, a world's leading research-based pharmaceutical, is focusing on research, development and manufacturing of medicines for people and animals. We strive to support people's lifelong health and well-being and contribute to improving quality of life through innovative and valuable products globally.